<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Phenylephrine (nasal): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Phenylephrine (nasal): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Phenylephrine (nasal): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9898" href="/d/html/9898.html" rel="external">see "Phenylephrine (nasal): Drug information"</a> and <a class="drug drug_patient" data-topicid="12285" href="/d/html/12285.html" rel="external">see "Phenylephrine (nasal): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F9504768"><span class="drugH1">Brand Names: US</span>
<ul>
<li>4-Way Fast Acting [OTC];</li>
<li>4-Way Menthol [OTC];</li>
<li>Neo-Synephrine Cold/Allrg Mild [OTC];</li>
<li>Neo-Synephrine Cold/Allrgy Ext [OTC];</li>
<li>Neo-Synephrine Cold/Allrgy Reg [OTC]</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F10513194"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Adrenergic Agonist Agent</span>;</li>
<li>
<span class="list-set-name">Alpha-Adrenergic Agonist</span>;</li>
<li>
<span class="list-set-name">Nasal Agent, Vasoconstrictor</span>;</li>
<li>
<span class="list-set-name">Sympathomimetic</span></li></ul></div>
<div class="block dop drugH1Div" id="F9504921"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aa6069be-77fb-4807-b092-cbf82db43773">Nasal congestion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nasal congestion:</b>
<b>Note:</b> Therapy should not exceed 3 days:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants and Children &lt;2 years: Limited data available: 0.5% solution: Intranasal: Instill 0.1 mL in each nostril as a single dose (Ralston 2008; Turner 1996). In a double-blind, placebo-controlled trial in 20 infants (mean age: 4 months) with bronchiolitis results showed, improved respiratory scores and oxygen saturation; however, statistical significance was not reached (Ralston 2008). In another randomized, double-blind, placebo-controlled trial, 23 pediatric patients (age range: 6 to 18 months) with the common cold showed improvement in nasal obstruction which was not considered significant; no effect on middle ear pressures was observed (Turner 1996).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years:</p>
<p style="text-indent:-2em;margin-left:6em;">2 to &lt;6 years: 0.125% solution: Intranasal: Instill 1 drop in each nostril every 2-4 hours as needed. <b>Note:</b> Consult product specific information for further details.</p>
<p style="text-indent:-2em;margin-left:8em;">Little Noses Decongestant: Instill 2 to 3 drops in each nostril every 4 hours as needed</p>
<p style="text-indent:-2em;margin-left:6em;">6 to 12 years: 0.25% solution: Intranasal: Instill 1 to 3 sprays in each nostril every 4 hours as needed</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: 0.25% to 1% solutions: Intranasal: Instill 1 to 3 drops or sprays every 4 hours as needed</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51153454"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51153455"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F9504922"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9898" href="/d/html/9898.html" rel="external">see "Phenylephrine (nasal): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aa6069be-77fb-4807-b092-cbf82db43773">Nasal congestion</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nasal congestion:</b> Intranasal: 0.25% to 1% solution: Instill 2 to 3 sprays in each nostril no more than every 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Duration:</i> Generally, limit to 3 to 5 days of consecutive use due to risk of rhinitis medicamentosa (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32707227','lexi-content-ref-25644617']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32707227','lexi-content-ref-25644617'])">Ref</a></span>). In patients with persistent symptoms despite use of first-line therapies, some guidelines suggest intranasal decongestants may be offered in combination with an intranasal corticosteroid for up to 4 weeks with low risk of rhinitis medicamentosa (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32707227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32707227'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990720"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">There are no dosage adjustments provided in manufacturer’s labeling. </p></div>
<div class="block doha drugH1Div" id="F50988072"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">There are no dosage adjustments provided in manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F9504796"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Nasal: Burning, nasal discharge, sneezing, stinging</p></div>
<div class="block war drugH1Div" id="F9504794"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Local nasal effects: Temporary discomfort such as burning, stinging, sneezing, or an increase in nasal discharge may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Rebound nasal congestion: Frequent or prolonged use may cause nasal congestion to recur or worsen.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with hypertension or heart disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes mellitus: Use with caution in patients with diabetes mellitus.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disease: Use with caution in patients with thyroid disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostatic hyperplasia/Urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Self-medication (OTC use): When used for self-medication (OTC), do not use &gt;3 days; discontinue use and notify health care provider if nervousness, dizziness, or sleeplessness occurs or if symptoms do not improve within 3 days; do not use if solution is brown or contains precipitates; do not exceed recommended dosages or use with other products containing decongestants.</p></div>
<div class="block foc drugH1Div" id="F9505016"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Nasal, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4-Way Fast Acting: 1% (29.6 mL) [contains benzalkonium chloride]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4-Way Menthol: 1% (14.8 mL, 29.6 mL) [contains benzalkonium chloride, menthol, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Neo-Synephrine Cold/Allrg Mild: 0.25% (15 mL) [contains benzalkonium chloride]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Neo-Synephrine Cold/Allrgy Ext: 1% (15 mL) [contains benzalkonium chloride]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Neo-Synephrine Cold/Allrgy Reg: 0.5% (15 mL) [contains benzalkonium chloride]</p></div>
<div class="block geq drugH1Div" id="F20452787"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322409"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (4-Way Fast Acting Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1% (per mL): $0.21</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (4-Way Menthol Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1% (per mL): $0.25</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Neo-Synephrine Cold/Allrg Mild Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25% (per mL): $0.26</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Neo-Synephrine Cold/Allrgy Ext Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1% (per mL): $0.29</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Neo-Synephrine Cold/Allrgy Reg Nasal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.5% (per mL): $0.26</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52614398"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">For intranasal use only. Clear nostrils before use; squeeze bottle with firm, quick pressure while inhaling into each nostril and gently occluding the other. Wipe nozzle clean after each use.</p></div>
<div class="block adm drugH1Div" id="F29043596"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">For intranasal use only. Blow nose to clear nostrils before use; squeeze bottle with firm, quick pressure while inhaling into each nostril and gently occluding the other. Wipe nozzle clean after each use.</p></div>
<div class="block sts drugH1Div" id="F25226358"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20ºC to 25ºC (68ºF to 77ºF); protect from light. </p></div>
<div class="block usep drugH1Div" id="F53570720"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Symptomatic relief of nasal and nasopharyngeal mucosal congestion (OTC products: FDA approved in adults; refer to product specific information regarding FDA approval in pediatric patients)</p></div>
<div class="block mst drugH1Div" id="F12782775"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Neo-Synephrine (phenylephrine, nasal) may be confused with Neo-Synephrine (oxymetazoline)</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299868"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F9504832"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alpha1-Blockers: May diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atropine (Systemic): May enhance the hypertensive effect of Alpha1-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromocriptine: May enhance the hypertensive effect of Alpha1-Agonists. Management: Consider alternatives to this combination when possible. If combined, monitor for hypertension and tachycardia, and do not coadminister these agents for more than 10 days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives (Vasoconstrictive CYP3A4 Substrates): May enhance the vasoconstricting effect of Alpha1-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Esketamine: Decongestants (Nasally Administered) may diminish the therapeutic effect of Esketamine.  Management: Patients who require a nasal decongestant on an esketamine dosing day should administer the nasal decongestant at least 1 hour before esketamine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: Decongestants may decrease the serum concentration of FentaNYL. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iobenguane Radiopharmaceutical Products: Alpha1-Agonists may diminish the therapeutic effect of Iobenguane Radiopharmaceutical Products.  Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. Do not administer these drugs until at least 7 days after each iobenguane dose.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the adverse/toxic effect of Sympathomimetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lisuride: May enhance the hypertensive effect of Alpha1-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists. While linezolid is expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to linezolid specific monographs for details.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pergolide: May enhance the hypertensive effect of Alpha1-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the therapeutic effect of Alpha1-Agonists. Tricyclic Antidepressants may diminish the therapeutic effect of Alpha1-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zavegepant: Decongestants (Nasally Administered) may decrease the serum concentration of Zavegepant.  Management: Avoid the concurrent administration of intranasal decongestants with zavegepant. If combined use is unavoidable, intranasal decongestants should be administered at least 1 hour after zavegepant administration.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F11391445"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">When administered intravenously, phenylephrine crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Decongestants are not recommended for the treatment of rhinitis during pregnancy (BSACI [Scadding 2017]). Use of phenylephrine nasal spray can be considered if acute relief is needed (Mazzotta 1999).</p></div>
<div class="block pha drugH1Div" id="F9504875"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Potent, direct-acting alpha-adrenergic agonist with virtually no beta-adrenergic activity; produces local vasoconstriction resulting in nasal decongestion.</p></div>
<div class="block phk drugH1Div" id="F10334904"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Intranasal: ≤2 minutes (Chua 1989)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: Intranasal: 2.5 to 4 hours (dose dependent) (Chua 1989)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10962001"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Neo synephrine</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Nostril</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  4 Way Fast Acting (phenylephrine) [prescribing information]. Warren, NJ: GSK Consumer Healthcare; 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23825816">
<a name="23825816"></a>Alhaddad ST, Khanna AK, Mascha EJ, Abdelmalak BB. Phenylephrine as an alternative to cocaine for nasal vasoconstriction before nasal surgery: a randomised trial. <i>Indian J Anaesth</i>. 2013;57(2):163-169. doi: 10.4103/0019-5049.111844.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenylephrine-nasal-pediatric-drug-information/abstract-text/23825816/pubmed" id="23825816" target="_blank">23825816</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2647163">
<a name="2647163"></a>Chua SS, Benrimoj SI, and Triggs EJ. Pharmacokinetics of non-prescription sympathomimetic agents. <i>Biopharm Drug Dispos</i>. 1989;10(1):1-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenylephrine-nasal-pediatric-drug-information/abstract-text/2647163/pubmed" id="2647163" target="_blank">2647163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32707227">
<a name="32707227"></a>Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: a practice parameter update. <i>J Allergy Clin Immunol</i>. 2020;146(4):721-767. doi:10.1016/j.jaci.2020.07.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenylephrine-nasal-pediatric-drug-information/abstract-text/32707227/pubmed" id="32707227" target="_blank">32707227</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Good Sense Nasal Four (phenylephrine) [prescribing information]. Allergan, MI: Perrigo; August 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10719965">
<a name="10719965"></a>Groudine SB, Hollinger I, Jones J, DeBouno BA. New York State guidelines on the topical use of phenylephrine in the operating room. The Phenylephrine Advisory Committee. <i>Anesthesiology</i>. 2000;92(3):859-864.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenylephrine-nasal-pediatric-drug-information/abstract-text/10719965/pubmed" id="10719965" target="_blank">10719965</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21271600">
<a name="21271600"></a>Higgins TS, Hwang PH, Kingdom TT, Orlandi RR, Stammberger H, Han JK. Systematic review of topical vasoconstrictors in endoscopic sinus surgery. <i>Laryngoscope</i>. 2011;121(2):422-432. doi: 10.1002/lary.21286.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenylephrine-nasal-pediatric-drug-information/abstract-text/21271600/pubmed" id="21271600" target="_blank">21271600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10230583">
<a name="10230583"></a>Mazzotta P, Loebstein R, Koren G. Treating allergic rhinitis in pregnancy. Safety considerations. <i>Drug Saf</i>. 1999;20(4):361‐375. doi:10.2165/00002018-199920040-00005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenylephrine-nasal-pediatric-drug-information/abstract-text/10230583/pubmed" id="10230583" target="_blank">10230583</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Phenylephrine HCl Injection [prescribing information]. Irvine, CA: Teva Parenteral Medicines Inc; October 2008.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18657831">
<a name="18657831"></a>Ralston S and Roohi M, "A Randomized, Controlled Trial of Nasal Phenylephrine in Infants Hospitalized for Bronchiolitis," <i>J Pediatr</i>, 2008, 153(6):795-8.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenylephrine-nasal-pediatric-drug-information/abstract-text/18657831/pubmed" id="18657831" target="_blank">18657831</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30239057">
<a name="30239057"></a>Scadding GK, Kariyawasam HH, Scadding G, et al. BSACI guideline for the diagnosis and management of allergic and non-allergic rhinitis (Revised Edition 2017; First edition 2007). <i>Clin Exp Allergy</i>. 2017;47(7):856‐889. doi:10.1111/cea.12953<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenylephrine-nasal-pediatric-drug-information/abstract-text/30239057/pubmed" id="30239057" target="_blank">30239057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25644617">
<a name="25644617"></a>Seidman MD, Gurgel RK, Lin SY, et al; Guideline Otolaryngology Development Group. AAO-HNSF. Clinical practice guideline: allergic rhinitis. <i>Otolaryngol Head Neck Surg.</i> 2015;152(1 suppl):S1-43. doi:10.1177/0194599814561600<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenylephrine-nasal-pediatric-drug-information/abstract-text/25644617/pubmed" id="25644617" target="_blank">25644617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10192668">
<a name="10192668"></a>Singer AJ, Konia N. Comparison of topical anesthetics and vasoconstrictors vs lubricants prior to nasogastric intubation: a randomized, controlled trial. <i>Acad Emerg Med</i>. 1999;6(3):184-190.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenylephrine-nasal-pediatric-drug-information/abstract-text/10192668/pubmed" id="10192668" target="_blank">10192668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8823858">
<a name="8823858"></a>Turner RB and Darden PM, "Effect of Topical Adrenergic Decongestants on Middle Ear Pressure in Infants With Common Colds," <i>Pediatr Infect Dis J</i>, 1996, 15(7):621-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/phenylephrine-nasal-pediatric-drug-information/abstract-text/8823858/pubmed" id="8823858" target="_blank">8823858</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 16038 Version 181.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
